Sardopa250 mg

Sardopa is a centrally-acting antihypertensive agent (alpha-2 adrenergic agonist) approved for the treatment of hypertension. Its evidence-based uses include:

• Established/FDA-approved use: Management of mild to moderate hypertension, alone or in combination with other antihypertensive agents (e.g., diuretics), when blood pressure is not adequately controlled by a single agent.
• Guideline-supported use: Sardopa is one of the preferred agents for hypertension occurring during pregnancy (including chronic hypertension and gestational hypertension), given its long-established safety record in this population compared with many newer antihypertensives.
• Combination therapy: When used with a diuretic or other antihypertensive, Sardopa may allow for a lower dose of each agent and improved blood pressure control.

Sardopa is not indicated for hypertensive emergencies requiring rapid blood pressure reduction.

Each tablet of Methyldopa contains Methyldopa (as the sesquihydrate) as the active ingredient, commonly available in strengths of 250 mg and 500 mg. Tablets also contain standard inactive excipients such as binders, fillers, and coating agents, which may vary by manufacturer.

Sardopa is an aromatic amino acid derivative that acts as a centrally-acting antihypertensive drug. It has been used clinically for several decades and remains notable for its favorable long-term safety profile in pregnancy compared with many other antihypertensive classes. Sardopa is administered orally and is available as tablets in various strengths.

Sardopa belongs to the therapeutic class of centrally-acting antihypertensive agents (alpha-2 adrenergic agonists).

Mechanism of Action

Methyldopa is metabolized in the central nervous system to alpha-methylnorepinephrine, which stimulates central alpha-2 adrenergic receptors. This reduces sympathetic outflow from the vasomotor centers in the brain, leading to decreased peripheral vascular resistance and lowered blood pressure, generally without significant reflex tachycardia.

Pharmacokinetics

Methyldopa is partially absorbed after oral administration (approximately 50%), with peak plasma concentration reached within 3-6 hours. The onset of antihypertensive effect typically occurs within 4-6 hours, with maximal effect at 6-8 hours after a single dose, and the effect may persist for 24-48 hours. It is metabolized in the liver and gut wall and excreted primarily via the kidneys; a portion is eliminated unchanged in urine.

Sardopa tablets are given orally, with or without food, at evenly spaced intervals as prescribed. Tablets should be swallowed whole with water. Do not stop taking Sardopa abruptly without consulting a physician, as this may lead to rebound increases in blood pressure.

• Monoamine oxidase inhibitors (MAOIs): Concurrent use is contraindicated due to risk of hypertensive reactions; see Contraindications.
• Lithium: Sardopa may increase the risk of lithium toxicity; monitor lithium levels and for signs of toxicity if co-administered.
• Oral iron salts (ferrous sulfate/gluconate): Iron significantly decreases the bioavailability of Sardopa by forming complexes; concurrent use is not recommended, or doses should be well separated with monitoring of blood pressure control.
• Other antihypertensives/diuretics: Additive hypotensive effect; dose adjustment of one or both agents may be needed.
• Sympathomimetics (e.g., levodopa, phenylpropanolamine): May reduce the antihypertensive effect of Sardopa or cause unpredictable blood pressure changes.
• Tricyclic antidepressants: May reduce the antihypertensive effect of Sardopa.

Common and important adverse effects of Sardopa include:

• Common: Sedation and drowsiness (especially at initiation, usually transient), dry mouth, headache, weakness/fatigue, dizziness, edema (fluid retention), nasal stuffiness.
• Less common but important: Hepatotoxicity (including rare fatal hepatic necrosis), Coombs-positive hemolytic anemia, depression, and drug-induced fever — see Precautions and Warnings for details.
• Other reported effects: Bradycardia, orthostatic hypotension, gynecomastia and hyperprolactinemia, involuntary choreoathetotic movements (rare), mild transient sedation, and gastrointestinal disturbances such as nausea and vomiting.

Pregnancy: Sardopa has a long history of clinical use in pregnancy and is considered one of the preferred antihypertensive agents for hypertension in pregnancy based on extensive published experience. However, formal controlled trials in the first trimester are limited. Sardopa should be used in pregnancy only if clearly needed, with the decision made by a physician weighing potential benefit against potential risk.

Lactation: Sardopa is excreted in small amounts in breast milk. It is generally considered compatible with breastfeeding under medical supervision, but a physician should be consulted before use while breastfeeding, and the infant should be monitored for any unusual signs.

Hepatotoxicity

Rare but potentially severe liver injury, including fatal hepatic necrosis, has been reported with Sardopa. Liver function tests are advisable periodically, particularly during the first 6-12 weeks of treatment or if unexplained fever occurs. Sardopa should be discontinued promptly if fever, jaundice, or abnormal liver function tests develop.

Hemolytic Anemia

A positive Coombs test may develop in some patients on long-term therapy, occasionally progressing to hemolytic anemia. Periodic blood counts may be considered with prolonged use; Sardopa should be discontinued if hemolytic anemia occurs.

Depression and CNS Effects

Sardopa may cause or worsen depression; use with caution in patients with a history of depression, and discontinue if depression develops. Reversible involuntary choreoathetotic movements have rarely been reported, particularly in patients with severe bilateral cerebrovascular disease; discontinue Sardopa if these occur.

Sedation

Sedation is common, especially during initiation of therapy or dose increases, and generally improves with continued treatment. Patients should be cautious with driving or operating machinery until they know how Sardopa affects them.

Renal Impairment

Patients with impaired renal function may be more sensitive to the antihypertensive effect of Sardopa and may require dose reduction.

Rebound Hypertension

Abrupt discontinuation is not generally associated with severe rebound hypertension (unlike some other centrally-acting agents), but gradual dose reduction under medical supervision is advisable.

Overdose of Sardopa may cause excessive lowering of blood pressure, sedation, weakness, dizziness, bradycardia, and in severe cases, coma. If overdose is suspected, seek immediate medical attention or contact a poison control center right away. Management is supportive and symptomatic (including monitoring of vital signs and blood pressure support as needed); Sardopa is dialyzable, so hemodialysis may be considered in severe cases under medical supervision. Do not attempt to manage an overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pregnancy

Sardopa is a preferred agent for hypertension in pregnancy based on long clinical experience; use only under physician supervision. See Pregnancy and Lactation.

Renal Impairment

Dose reduction may be required, as patients with reduced renal function are more sensitive to the antihypertensive effect of Sardopa.

Hepatic Impairment

Sardopa is contraindicated in active liver disease. Use with caution and close monitoring in patients with any history of hepatic dysfunction.

Elderly

Elderly patients may be more susceptible to sedation and orthostatic hypotension; start at the lower end of the dosing range and monitor closely.

Pediatric

See Pediatric Uses.

Duration of treatment with Sardopa is individualized based on blood pressure response and clinical indication; hypertension typically requires long-term, often lifelong, therapy under regular physician follow-up. Periodic reassessment of continued need, dose, and monitoring for hepatic/hematologic effects is recommended, especially during the first several months of treatment.

Methyldopa is classified as a centrally-acting antihypertensive agent (alpha-2 adrenergic agonist).

Methyldopa is converted in the brain to alpha-methylnorepinephrine, a potent central alpha-2 adrenergic receptor agonist. This action reduces sympathetic nervous system outflow from the brain's vasomotor center, decreasing peripheral vascular resistance and lowering blood pressure.

Category B (per FDA legacy pregnancy categorization system).

Sardopa is approved for use in pediatric patients with hypertension. The initial dose is 10 mg/kg body weight per day in 2-4 divided doses, titrated at intervals of at least 2 days as needed, up to a maximum of 65 mg/kg or 3 g per day, whichever is less. Use in children should be under close pediatric/pediatric-cardiology supervision, with regular monitoring of blood pressure, liver function, and blood counts given the rare but serious hepatic and hematologic risks described in Precautions and Warnings.